We first assessed the ability of VCX to inhibit the growth and proliferation of three breast cancer cell lines of different molecular subtypes, SKBR-3 (HER2+), MCF-7 (ER+), and MDA-MB-231 (TNBC). Here, ESR1 is linked to breast cancer.